Last reviewed · How we verify

NCT06038669

User Evaluation of a Home-collection Kit for People With Diabetes

Active, enrolled Last updated 27 March 2026
What this trial tests

trial testing Dried blood spot device in Diabetes in 63 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
20 February 2024
Primary endpoint
31 March 2025
31 December 2026

Quick facts

Lead sponsorUniversity Hospitals of North Midlands NHS Trust
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment63
Start date20 February 2024
Primary completion31 March 2025
Estimated completion31 December 2026
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University Hospitals of North Midlands NHS Trust

Who can join

Adults 18 to 90, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Type 1 and Type 2 are the most common types of diabetes mellitus. Although the cause of Type 1 is different to Type 2, they can both lead to high blood glucose levels as the patient is unable to store and use sugar. The disease is an epidemic of the 21st century which is increasing, having a current prevalence of approximately 8%. Poor disease control is associated with a range of long-term health conditions which have a severe impact upon quality of life and are responsible for the increased morbidity and mortality associated with the disease. Healthcare professionals use HbA1c as the main marker to monitor diabetic control. Patients with diabetes have regular review appointments to monitor their overall health and discuss their HbA1c target and results. The purpose of monitoring patients with diabetes is to improve patient outcomes. It is known that poor control is associated with poor clinical outcomes and also that reduced monitoring is linked to suboptimal diabetic control. Therefore, aiming for the correct monitoring frequency helps towards achieving the best control which can lead to the most favourable clinical outcomes. The inconvenience of attending for a blood test and follow-up appointment is a major factor affecting patient adherence to monitoring, locally approximately 50% of patients with diabetes have their HbA1c level measured either too soon or too late. To address this issue and improve access to monitoring at the correct time interval we aim to produce a HbA1c home testing kit which can be posted back to the laboratory at the convenience of the patient. The kit will be developed based on feedback from patients with diabetes and will use a dried blood spot sample to produce HbA1c results comparable to the whole blood standard method.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

Other University Hospitals of North Midlands NHS Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06038669.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing